Hematopoietic Stem Cell TransplantationTransplantation, HomologousGraft vs Host DiseaseTransplantation ConditioningStem Cell TransplantationHematologic NeoplasmsGraft SurvivalTissue DonorsBusulfanTreatment OutcomeTransplantation, AutologousPeripheral Blood Stem Cell TransplantationMyeloablative AgonistsTransplantation ChimeraImmunosuppressive AgentsBone Marrow TransplantationGraft vs Leukemia EffectCytomegalovirus InfectionsGraft vs Tumor EffectRetrospective StudiesRecurrenceVidarabineStem CellsRemission InductionHistocompatibility TestingKidney TransplantationSurvival RateGraft RejectionWhole-Body IrradiationLeukemia, Myeloid, AcuteLeukemiaCorneal TransplantationHematopoietic Stem CellsSurvival AnalysisDisease-Free SurvivalSiblingsMinor Histocompatibility AntigensCord Blood Stem Cell TransplantationTime FactorsLiver TransplantationHistocompatibilityMyelodysplastic SyndromesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCombined Modality TherapyHeart TransplantationChimerismPrecursor Cell Lymphoblastic Leukemia-LymphomaMultiple MyelomaSalvage TherapyLymphocyte TransfusionLymphocyte DepletionAntiviral AgentsT-LymphocytesHLA AntigensAcute DiseaseHematologic DiseasesAntilymphocyte SerumFollow-Up StudiesVirus ActivationCyclophosphamideNeoplasm, ResidualUnrelated DonorsAntineoplastic Combined Chemotherapy ProtocolsHepatic Veno-Occlusive DiseaseCytomegalovirusMelphalanImmunosuppressionCorneal NeovascularizationMice, Inbred C57BLCyclosporinePrognosisHematopoietic Stem Cell MobilizationAntigens, CD34Lymphoproliferative DisordersAnemia, AplasticImmunocompromised HostAntineoplastic AgentsMesenchymal Stem Cell TransplantationCell TransplantationTransplantation ImmunologyLymphoma, Non-HodgkinRoseolovirus InfectionsPrimary MyelofibrosisMycosesRisk FactorsTransplantationLiving DonorsLeukemia, MyeloidBone Marrow CellsDonor SelectionEmbryonic Stem CellsOpportunistic InfectionsLeukemia, Myeloid, Accelerated PhaseCytarabineBenzamidesFusion Proteins, bcr-ablGanciclovirCell DifferentiationLymphomaPyrimidines